ArticlePharmacoEconomics - open2020

Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.

S Boyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.